OncoMatch/Clinical Trials/NCT06500052
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Is NCT06500052 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BL-M17D1 for esophageal cancer.
Treatment: BL-M17D1 — This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Pancreatic Cancer
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Required: HER2 (ERBB2) overexpression (positive HER2 / low expression)
locally advanced or metastatic positive HER2 / low expression of the digestive tract tumor and other solid tumor
Disease stage
Metastatic disease required
locally advanced or metastatic positive HER2 / low expression of the digestive tract tumor and other solid tumor; Must have at least one measurable lesion according to RECIST v1.1 definition
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy or biological therapy
Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose
Cannot have received: mitomycin (mitomycin)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: nitrosoureas (nitrosoureas)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: antimetabolite (fluorouracil)
Oral drugs such as fluorouracil
Lab requirements
Cardiac function
no severe cardiac dysfunction, left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify